TW201004648A - Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides - Google Patents

Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides Download PDF

Info

Publication number
TW201004648A
TW201004648A TW098117016A TW98117016A TW201004648A TW 201004648 A TW201004648 A TW 201004648A TW 098117016 A TW098117016 A TW 098117016A TW 98117016 A TW98117016 A TW 98117016A TW 201004648 A TW201004648 A TW 201004648A
Authority
TW
Taiwan
Prior art keywords
group
compound
oligonucleotide
peg
independently
Prior art date
Application number
TW098117016A
Other languages
English (en)
Chinese (zh)
Inventor
Hong Zhao
Prasanna Reddy
Original Assignee
Enzon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc filed Critical Enzon Pharmaceuticals Inc
Publication of TW201004648A publication Critical patent/TW201004648A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/10—Vectors comprising a non-peptidic targeting moiety

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW098117016A 2008-05-23 2009-05-22 Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides TW201004648A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5586908P 2008-05-23 2008-05-23
US5595008P 2008-05-23 2008-05-23
US10657608P 2008-10-19 2008-10-19
US10657808P 2008-10-19 2008-10-19

Publications (1)

Publication Number Publication Date
TW201004648A true TW201004648A (en) 2010-02-01

Family

ID=41340917

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098117016A TW201004648A (en) 2008-05-23 2009-05-22 Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides

Country Status (6)

Country Link
US (1) US20110105413A1 (enExample)
EP (1) EP2288261A4 (enExample)
JP (1) JP2011520983A (enExample)
CA (1) CA2723263A1 (enExample)
TW (1) TW201004648A (enExample)
WO (1) WO2009143412A2 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2695532A1 (en) * 2007-08-20 2009-02-26 Enzon Pharmaceuticals, Inc. Polymeric linkers containing pyridyl disulfide moieties
ITMI20131929A1 (it) * 2013-11-20 2015-05-21 Domenico Terenzio Coniugato dell'acido folico e dell'indolo-3-carbinolo per uso medico
US10300070B2 (en) 2014-03-27 2019-05-28 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
IL259658B2 (en) 2016-01-08 2024-06-01 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with reduced side-effects
PL3400019T3 (pl) 2016-01-08 2023-01-23 Ascendis Pharma Growth Disorders A/S Proleki cnp z przyłączeniem nośnika w ugrupowaniu pierścieniowy
US11389510B2 (en) 2016-01-08 2022-07-19 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
IL297375B2 (en) 2016-01-08 2024-02-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low NPR–C binding
MX2018008061A (es) 2016-01-08 2018-08-23 Ascendis Pharma Growth Disorders As Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.
EP3400018A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with increased nep stability
FI3423103T3 (fi) 2016-03-01 2024-11-20 Ascendis Pharma Bone Diseases As PTH-aihiolääkkeitä
US11896671B2 (en) 2016-07-13 2024-02-13 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
MY199903A (en) 2016-09-29 2023-11-28 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
DK3518960T5 (da) 2016-09-29 2024-09-02 Ascendis Pharma Bone Diseases As Doseringsskema for en PTH-forbindelse med kontrolleret frigivelse
HRP20250102T1 (hr) 2016-09-29 2025-03-28 Ascendis Pharma Bone Diseases A/S Pth spojevi s kontroliranim oslobađanjem
CN109789188B (zh) 2016-09-29 2023-07-14 阿森迪斯药物骨疾病股份有限公司 具有低峰-谷比的pth化合物
CN110891611B (zh) 2017-03-22 2024-03-29 阿森迪斯制药公司 水凝胶交联透明质酸前药组合物和方法
MA52662A (fr) 2018-03-28 2021-02-17 Ascendis Pharma Oncology Div A/S Conjugués d'il-2
WO2019185706A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Conjugates
BR112020022306A2 (pt) 2018-05-18 2021-02-23 Ascendis Pharma Bone Diseases A/S dose de partida de conjugados de pth
WO2020064847A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Degradable hyaluronic acid hydrogels
CA3114056A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Treatment of infections
MX2021003186A (es) 2018-09-26 2021-07-16 Ascendis Pharma As Nuevos conjugados de hidrogel.
SG11202105833WA (en) 2019-01-04 2021-07-29 Ascendis Pharma Oncology Div A/S Minimization of systemic inflammation
JP2022516314A (ja) 2019-01-04 2022-02-25 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス 自然免疫アゴニストのための持続性局所性薬物レベル
MX2021007706A (es) 2019-01-04 2021-08-05 Ascendis Pharma Oncology Div A/S Conjugados de agonistas de receptor de reconocimiento de patron.
EP3906018A1 (en) 2019-01-04 2021-11-10 Ascendis Pharma Oncology Division A/S Induction of sustained local inflammation
KR20250171437A (ko) 2019-02-11 2025-12-08 아센디스 파마 본 디지즈 에이/에스 Pth 접합체의 액체 약학 제제
KR102893903B1 (ko) 2019-02-11 2025-12-01 아센디스 파마 그로우쓰 디스오더스 에이/에스 Cnp 접합체의 건조 약학 제제
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
US20230102309A1 (en) 2019-06-21 2023-03-30 Ascendis Pharma Oncology Division A/S Tyrosine kinase inhibitor conjugates
EP3986479A1 (en) 2019-06-21 2022-04-27 Ascendis Pharma Oncology Division A/S Anti-ctla4 conjugates
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
BR112022010419A2 (pt) 2020-01-13 2022-08-23 Ascendis Pharma Bone Diseases As Tratamento de hipoparatireoidismo
AU2021269007A1 (en) 2020-05-04 2022-11-24 Ascendis Pharma A/S Hydrogel irradiation
TW202210502A (zh) 2020-06-03 2022-03-16 丹麥商阿森迪斯腫瘤製藥有限公司 新穎il-2序列及其用途
AU2021335032A1 (en) 2020-08-28 2023-03-09 Ascendis Pharma Oncology Division A/S Glycosylated IL-2 proteins and uses thereof
MX2023003540A (es) 2020-09-28 2023-04-21 Ascendis Pharma Bone Diseases As Mejora del bienestar fisico y mental de los pacientes con hipoparatiroidismo.
KR20230164709A (ko) 2021-04-01 2023-12-04 아센디스 파마 에이에스 염증 유발 질환을 치료하기 위한 지속형 성장 호르몬의 용도
AU2022266383A1 (en) * 2021-04-28 2023-11-16 Japan Science And Technology Agency Artificial nucleic acid and nucleic acid delivering method using same
KR20240082355A (ko) 2021-09-22 2024-06-10 아센디스 파마 본 디지즈 에이/에스 장시간 작용형 pth 화합물 치료
WO2023110727A2 (en) 2021-12-13 2023-06-22 Ascendis Pharma Oncology Division A/S Novel cancer treatments with tlr7/8 agonists
WO2023110758A1 (en) 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
CA3249311A1 (en) 2022-05-23 2023-11-30 Ascendis Pharma Growth Disorders A/S LIQUID PHARMACEUTICAL FORMULATIONS OF CNP COMPOUNDS
JP2025537527A (ja) 2022-11-02 2025-11-18 アセンディス ファーマ ボーン ディジージズ エー／エス ２つのｐｔｈ化合物を含むｐｔｈ治療レジメン
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
TW202430223A (zh) 2023-01-05 2024-08-01 丹麥商阿仙帝斯眼科製藥有限公司 用於治療眼部病症之藥物結合物
TW202434299A (zh) 2023-01-05 2024-09-01 丹麥商阿仙帝斯製藥公司 製造水凝膠微球之方法
WO2024184354A1 (en) 2023-03-06 2024-09-12 Ascendis Pharma A/S Multi-albumin binding compounds
CN120826239A (zh) 2023-03-06 2025-10-21 阿森迪斯药物股份有限公司 包含白蛋白结合部分的药物化合物
AU2024232125A1 (en) 2023-03-06 2025-08-28 Ascendis Pharma A/S Compounds of drugs with an albumin binding moiety
CN121219011A (zh) 2023-03-20 2025-12-26 阿森迪斯药物生长障碍股份有限公司 治疗患有软骨发育不全患者胸腰椎畸形的方法
CN121175071A (zh) 2023-05-09 2025-12-19 阿森迪斯药物肿瘤股份有限公司 使用il-2缀合物的新型癌症治疗方法
WO2025051711A1 (en) 2023-09-04 2025-03-13 Ascendis Pharma Bone Diseases A/S Pth treatment of chronic kidney disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2222689T3 (es) * 1998-03-12 2005-02-01 Nektar Therapeutics Al, Corporation Derivados del polietilenglicol con grupos reactivos proximales.
CA2465206C (en) * 2001-11-09 2010-01-26 Enzon, Inc. Polymeric thiol-linked prodrugs
EP1581582B2 (en) * 2003-01-06 2017-06-07 Nektar Therapeutics Thiol-selective water-soluble polmer derivatives
US20050266409A1 (en) * 2003-02-04 2005-12-01 Wyeth Compositions and methods for diagnosing, preventing, and treating cancers
MXPA05011022A (es) * 2003-04-13 2006-04-27 Enzon Pharmaceuticals Inc Profarmacos oligonucleotidos polimericos.
MX2007007471A (es) * 2004-12-21 2007-07-20 Nektar Therapeutics Al Corp Reactivos de tiol polimericos estabilizados.
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
AU2007296055A1 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
JP2010503708A (ja) * 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド 多官能性リンカーを含む標的化ポリマープロドラッグ
US8367065B2 (en) * 2006-09-15 2013-02-05 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
KR20090108082A (ko) * 2007-02-09 2009-10-14 엔존 파마슈티컬즈, 인코포레이티드 7-에틸-10-하이드록시캄토테신 다분지형 고분자 접합체를 이용한 내성 또는 불응성 암의 치료방법
CA2695532A1 (en) * 2007-08-20 2009-02-26 Enzon Pharmaceuticals, Inc. Polymeric linkers containing pyridyl disulfide moieties

Also Published As

Publication number Publication date
WO2009143412A3 (en) 2010-04-15
EP2288261A2 (en) 2011-03-02
US20110105413A1 (en) 2011-05-05
JP2011520983A (ja) 2011-07-21
EP2288261A4 (en) 2013-09-25
WO2009143412A2 (en) 2009-11-26
CA2723263A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
TW201004648A (en) Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
CN102231951A (zh) 用于核酸传递系统的可释放的偶联物
CN111902148A (zh) 治疗肌萎缩和强直性肌营养不良的组合物和方法
CN117858948A (zh) 新的治疗剂递送部分及其用途
KR20090055623A (ko) 올리고뉴클레오티드 전달을 위한 방해된 에스테르 기재 생분해성 링커
TW201019969A (en) Branched cationic lipids for nucleic acids delivery system
CN116785445B (zh) 靶向化学药物及其制备方法、药物组合物、靶向化学药物的应用
KR20240099149A (ko) 뒤센 근이영양증에서 엑손 45를 스키핑하기 위한 조성물 및 방법
JP2010510810A (ja) ポリマー低分子干渉ｒｎａ複合体
US12054714B2 (en) Peptide docking vehicle for targeted nucleic acid delivery
US20250129365A1 (en) Compounds and methods for skipping exon 44 in duchenne muscular dystrophy
WO2024073042A1 (en) Ocular delivery of therapeutic agents
CN118434451A (zh) 缀合物与组合物及制备方法和用途
TW201038288A (en) Methods for inhibiting angiogenesis with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
US8110559B2 (en) Hindered ester-based biodegradable linkers for oligonucleotide delivery
US20250325675A1 (en) Aptamer, conjugate, composition, method for preparing same, and use thereof
CN118215504A (zh) 用于跳跃杜兴氏肌营养不良中的外显子44的化合物和方法
WO2021191208A1 (fr) Copolymère linéaire pour la transfection de gènes
CN116801885A (zh) 用于抑制DUX4表达的RNAi试剂、其组合物和使用方法
CN118434863A (zh) 缀合物与组合物及制备方法和用途